CIAM
TSHA icon

Caitong International Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Caitong International Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6K Buy
1,855
+929
+100% +$5.5K ﹤0.01% 1101
2026
Q1 		$4.14K Sell
926
-24,651
-96% -$115K ﹤0.01% 1158
2025
Q4 		$141K Buy
25,577
+22,373
+698% +$109K 0.03% 302
2025
Q3 		$10.5K Buy
3,204
+1,057
+49% +$2.99K 0.01% 1002
2025
Q2 		$4.96K Buy
2,147
+1,333
+164% +$2.9K ﹤0.01% 1014
2025
Q1 		$1.13K Buy
+814
New +$1.36K ﹤0.01% 1536

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Caitong International Asset Management's TSHA Position: Q2 2026 in Review

Caitong International Asset Management increased its Taysha Gene Therapies (TSHA) stake by 100% in Q2 2026, buying an estimated $5.5K and bringing the position to 1,855 shares worth $12.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1101.

Caitong International Asset Management first reported a position in TSHA in Q1 2025 and has held it in 6 quarters since. The position peaked at $141K in Q4 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Caitong International Asset Management held 1,855 shares of Taysha Gene Therapies worth $12.6K as of Q2 2026.
  • Caitong International Asset Management bought 929 Taysha Gene Therapies shares in Q2 2026, an estimated $5.5K.
  • Taysha Gene Therapies made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1101 holding.
  • Caitong International Asset Management first reported a position in Taysha Gene Therapies in Q1 2025 and has held it in 6 quarters since.
  • Caitong International Asset Management's Taysha Gene Therapies position peaked at $141K in Q4 2025.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.